Phaseline

Targets › MRPL3

MRPL3 (Large ribosomal subunit protein uL3m): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Infectious disease; next expected readout May 2027.

Open in Phaseline: the race on MRPL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Semmelweis UniversityTazobactam
Bacterial beta-lactamase TEM inhibitor
MRPL3Phase 4InfectionAug 2028
Boston UniversityLinezolid
Bacterial 70S ribosome inhibitor
MRPL3Phase 2Tuberculosis, Multidrug-ResistantMay 2027

Conditions

Infection (1) Tuberculosis, Multidrug-Resistant (1)

Modalities

small molecule (2)

Companies

Semmelweis University (1) Boston University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.